ClinicaliQ Trial Snapshot
- Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) — Recruiting • Phase III • Oncology • NCT07405164.
- What is being tested: Belzutifan (MK-6482), a hypoxia-inducible factor (HIF-2α) inhibitor, is being evaluated in an extension study for patients with advanced solid tumors and VHL-related malignancies that have either metastasized or are unresectable by surgery.
- Patient eligibility overview: This extension study enrolls participants who have completed prior belzutifan trials and demonstrated clinical benefit or stable disease; eligibility requires adequate organ function, performance status, and absence of active secondary malignancies or uncontrolled medical conditions.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: * Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids * VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer Researchers want…
Eligibility Snapshot
- : The main inclusion criteria include but are not limited to the following: * Participants with advanced solid tumors or von Hippel-Lindau-related neoplasms who are participating in belzutifan-containing studies and on active treatment in a belzutifan parent study.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.